Preliminary programs 2017

WednesdaySeptember 27
Coffe and sandwich will be served from 08.30
09.00-10.00Registration
Opening session
(Magnus Gisslén, Sweden, Nina Weis, Denmark)
10.15-10.20Welcome (Magnus Gisslén, Sweden and Nina Weis, Denmark)
10.20-10.50Opening Plenary 1
Persistent immunological problems in the ART era (Francesca Chiodi, Sweden)
10.50-11.00Discussion
Plenary Session I – Immune reconstitution inflammatory syndrome (IRIS)
(Veronica Svedhem Johansson, Sweden, Matti Ristola, Finland)
11.00-11.25Plenary 2
Pathogenic and clinical aspects on IRIS in HIV (Irini Sereti, USA)
11.25-11.35Discussion
11.35-12.00Plenary 3
Integrase inhibitors and the risk of IRIS (Bart Rijnders, The Netherlands)
12.00-12.10Discussion
12.10-13.10Lunch
Plenary Session II – ART
(Anders Sönnerborg, Sweden, Arild Maeland, Norway)
13.10-13.35Plenary 4
Injectable drugs and other long-acting agents against HIV (Jan Gerstoft, Denmark)
13.35-13.45Discussion
13.45-14.10Plenary 5
Is HIV management moving towards personalized medicine? (Carlo-Federico Perno, Italy)
14.10-14.20Discussion
14.20-14.45Plenary 6
Clinical use of HIV DNA quantification and genotyping.
(Maurizio Zazzi, Italy)
14.45-14.55Discussion
14.55-15.20Plenary 7
The threat of increasing HIV drug resistance and the need for global action (Silvia Bertagnolio, Switzerland)
15.20-15.30Discussion
15.30-15.45Short break
Abstract Session I
(Annika Karlsson, Sweden, Leo Flamholc, Sweden)
15.45-16.00Oral 1 (10 min + 5 min discussion)
CSF Anti-HIV Antibody Decline by Early Antiretroviral Therapy Suggests Reduced HIV Persistence in the CNS. (Magnus Gisslén, Sweden)
16.00-16.15Oral 2
Suppressive antiretroviral therapy is associated with effective treatment of high-grade cervical intraepithelial neoplasia. (Christina Carlander, Sweden)
16.15.16.30Oral 3
Decreasing HIV-1 incidence and undiagnosed HIV-1 cases in Sweden based on multiple biomarker estimate of infection times. (Jan Albert, Sweden)
16.30-16.45Oral 4
Genome wide association studies to characterize the HIV-1 positive Elite Controller (EC) cohort in Sweden. (Sara Svensson Akusjärvi, Sweden)
16.45-17.15Coffee and exhibition/posters
17.15-18.15Satellite Symposium I – GSK/ViiV
Dolutegravir – from development to real-life safety and universal access (Annemiek de Ruiter, Senior Global Medical Director, ViiV Healthcare and Eva Fernvik, PhD, Senior Scientific Advisor GSK/ ViiV Healthcare)
18.15-18.25Short break
18.25-19.25Satellite Symposium II – Janssen (HIV)
CNS Complications in HIV Patients
(Lars Østergaard/Steffen Leth Denmark, Aylin Yilmaz/Erika Ahlgren Sweden, Paola Cinque, Italy)
19.25-Poster Exhibition with cheese and snacks

ThursdaySeptember 28
08.00-09.00Satellite Symposium III – Gilead
HIV and Women (Christina Carlander, moderator, & Teresa Katzenstein)
09.00-09.10Short break
Plenary Session III – Last year’s most important achievements in the HIV research field
(Francesca Chiodi, Sweden Anders Blaxhult, Sweden)
09.10-09.40Plenary 8
Top 5 in basic HIV research 2016/17 (Johan Sandberg, Sweden)
09.40-09.50Discussion
09.50-10.20Plenary 9
Top 5 in clinical HIV research 2016/17 (Aylin Yilmaz, Sweden)
10.20-10.30Discussion
10.30-11.00Coffee and exhibition/posters
Plenary Session IV – Reservoirs and cure
(Helene Mens, Denmark, Magnús Gottfreðsson, Iceland)
11.00-11.30Plenary 10
Functional cure by integrin antibody therapy? (Aftab Ansari, USA)
11.30-11.40Discussion
11.40-12.10Plenary 11
“Soothe and snooze” as an alternative to “kick and kill” (Susana Valente, USA)
12.10-12.20Discussion
12.20-12.50Plenary 12
Stem cell transplantations – status post-the Berliner and Boston-patients (Javier Martinez-Picado, Spain)
12.50-13.00Discussion
13.00-14.00Lunch
Plenary Session V – Complications, co-morbidities etc.
(Jan Gerstoft, Denmark, Magnus Gisslén, Sweden)
14.00-14.30Plenary 13
Protease inhibitors and risk of cardio-/cerebro-vascular disease (Ann-Brit Eg Hansen, Denmark)
14.30-14.40Discussion
14.40-15.10Plenary 14
Symptomatic CNS escape including CD8-encephalitis during cART (Paola Cinque, Italy)
15.10-15.20Discussion
15.20-15.30HIV & Hepatitis Nordic Conference 2017 Abstract Award
(Introduction: Sophie Ekman, Sweden) (Anders Sönnerborg, Sweden)
15.30-16.00Coffee and exhibition/posters
16.00-17.00Satellite Symposium IV – Abbvie (HCV)
The era of pan-genotypic next generation HCV treatment
(Jean-Michel Pawlotsky, France)
17.00-17.10Short break
17.10-18.10Satellite Symposium V – Gilead
Många personer som injicerar droger står utan hepatit C‐vård.
• Hur kan vi i Sverige ge optimal hjälp?
En paneldebatt modererad av Barbro Westerholm, riksdagsledamot Liberalerna.
Deltagare: Fred Nyberg, Professor, U-Fold, Uppsala Universitet, Martin Kåberg, medicinskt ansvarig sprutbytet Stockholm, Marianne Alanko Blomé, medicinskt ansvarig sprutbytet Malmö, Anders Nystedt, Smittskyddsläkare, Luleå, Lars-Håkan Nilsson, Medicinskt ansvarig Kriminalvården
Aprx. 19.30Conference dinner

FridaySeptember 29
08.00-09.00Satellite Symposium VI – MSD (HCV)
Towards HCV-Elimination in the Nordics (Olav Dalgard, Hannah Fraser, Martin Kåberg, Lars Peters, Knut Bo Kieland, Henrikki Brummer-Korvenkontio)
Plenary Session VI – Last year’s most important achievements in the hepatitis field
(Ola Weiland, Sweden)
09.10-09.40Plenary 15
Top 5 in hepatitis research 2016/17 (Soo Aleman, Sweden)
09.40-09.50Discussion
Abstract Session II
(Martti Färkkilä, Finland Olav Dalgard, Norway)
09.50-10.05Oral 5 (10 + 5 min discussion)
High BMI, pre-treatment cirrhosis and older age increase the risk for persisting advanced fibrosis after SVR in patients with chronic HCV. (Magnus Hedenstierna, Sweden)
10.05-10.20Oral 6
Increased NK cell function after cessation of long-term NUC treatment in chronic hepatitis B associates with liver damage and HBsAg loss. (Niklas K. Björkström, Sweden)
10.20-11.00Coffee and exhibition/posters
Plenary Session VII – Hepatitis B
(Nina Weis, Denmark, Leo Flamholc, Sweden)
11.00-11.30Plenary 16
Immunopathology and immunotherapy in HBV (Mala Maini, UK)
11.30-11.40Discussion
11.40-12.10Plenary 17
Are HBV DNA integrations relevant, and is HBV RNA a useful clinical marker? (Magnus Lindh, Sweden)
12.10-12.20Discussion
12.20-13.20Lunch
Plenary Session VIII – Hepatitis C
(Soo Aleman, Sweden, Matti Sällberg, Sweden)
13.20-13.50Plenary 18
Pangenotypic and shorter treatment (Christophe Hézode, France)
13.50-14.00Discussion
14.00-14.30Plenary 19
Immunomodulation during DAA treatment and the clinical impact (Robert Thimme, Germany)
14.30-14.40Discussion
14.40-15.10Plenary 20
HCV vaccines - an overview (Judith Gottwein, Denmark)
15.10-15.20Discussion
15.20-15.30Concluding remarks